Opinion|Podcasts|November 1, 2024
Pathophysiology of CSU and Role of BTK
Key Takeaways
- CSU pathogenesis involves complex mechanisms, including mast cell activation and degranulation, contributing to the condition's symptoms.
- Novel mechanisms of mast cell activation have been identified, enhancing understanding of CSU and revealing potential therapeutic targets.
Panelists discuss recent insights into the mechanisms involved in chronic spontaneous urticaria (CSU) pathogenesis, emphasizing how the identification of novel mast cell activation pathways enhances our understanding of the condition, particularly highlighting the role of Burton tyrosine kinase (BTK) as a key mediator in mast cell degranulation and histamine release.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What have we learned about the possible mechanisms involved with CSU pathogenesis?
- How has the identification and characterization of novel mechanisms of mast cell activation helped us to better understand CSU?
- Can you describe the role of BTK as a mediator in mast cell degranulation and histamine release?
Advertisement
Related to this article
Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Advertisement
Advertisement
Trending on HCPLive
1
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
2
Sibeprenlimab Stabilizes eGFR Over 24 Months in IgA Nephropathy: VISIONARY
3
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
4
Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD
5